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Abstract
Following the Institute of Medicine's 2009 report on the national priorities for comparative 
effectiveness research (CER), funding for support of CER became available in 2009 through the 
American Recovery and Reinvestment Act. The Centers for Disease Control and Prevention 
(CDC) received funding to enhance the infrastructure of population-based cancer registries and to 
expand registry data collection to support CER. The CDC established 10 specialized registries 
within the National Program of Cancer Registries (NPCR) to enhance data collection for all 
cancers and to address targeted CER questions, including the clinical use and prognostic value of 
specific biomarkers. The project also included a special focus on detailed first course of treatment 
for cancers of the breast, colon, and rectum, as well as chronic myeloid leukemia (CML) 
diagnosed in 2011. This paper describes the methodology and the work conducted by the CDC 
and the NPCR specialized registries in collecting data for the 4 special focused cancers, including 
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the selection of additional data variables, development of data collection tools and software 
modifications, institutional review board approvals, training, collection of detailed first course of 
treatment, and quality assurance. It also presents the characteristics of the study population and 
discusses the strengths and limitations of using population-based cancer registries to support CER 
as well as the potential future role of population-based cancer registries in assessing the quality of 
patient care and cancer control.
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Introduction
In June 2009, the Institute of Medicine (IOM) published a report entitled Initial National 
Priorities for Comparative Effectiveness Research (CER) and listed 100 CER priorities, 
including cancer-related objectives.1 The IOM defined CER as “the generation and synthesis 
of evidence that compares the benefits and harms of alternative methods to prevent, 
diagnose, treat, and monitor a clinical condition or to improve the delivery of care. The 
purpose of CER is to assist consumers, clinicians, purchasers, and policy makers to make 
informed decisions that will improve health care at both individual and population levels.”1 
Funding for CER was provided to the Department of Health and Human Services (HHS) 
through the American Recovery and Reinvestment Act (ARRA) of 2009, and projects were 
coordinated through the Agency for Healthcare Research and Quality (AHRQ).
The Centers for Disease Control and Prevention (CDC) received funding to enhance the 
infrastructure of population-based cancer registries and to support collection of data for 
CER. CDC developed a project entitled Enhancing Cancer Registry Data for Comparative 
Effectiveness Research (CER) and in 2010 awarded funds to ICF International and state 
cancer registries for expanded data collection and 6 special projects. Ten states receiving 
National Program of Cancer Registries (NPCR) funding that met the eligibility criteria were 
selected for the CER project based on competitive proposals and were established as 
specialized cancer registries. These registries had the potential and capability to enhance 
their infrastructure for “additional data collection, training, methodological development, 
and expansion of electronic reporting with the goal of supporting comparative effectiveness 
research and to develop sustainable methods to enhance registry data for public health and 
research.” As part of this CER project, participating NPCR specialized registries expanded 
data collection to include additional data variables, such as height, weight and smoking 
status, for all cancers, and they performed linkages with secondary data sets including 
census data, National Death Index files, hospital discharge data, and the state's breast and 
cervical cancer early detection programs to enhance registry data. The project also included 
a special focus on detailed treatment information for cancers of the breast, colon, and rectum 
as well as chronic myeloid leukemia (CML). An outcome of the project included a dataset 
that could be used for CER and other research. This paper provides a description of the 
methodology and the work conducted by the CDC and the NPCR specialized registries in 
collecting data for the 4 special focused cancers. It also presents the characteristics of the 
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study population and a discussion of the strengths and limitations of using population-based 
cancer registries to support CER.
Objectives
The primary objectives of the CER project were to enhance the registry infrastructure and to 
obtain data that would support CER for cancers of the breast, colon, and rectum as well as 
CML. The collected data included tumor characteristics (predictive and prognostic 
biomarkers), stage at diagnosis, first course of treatment (both neoadjuvant and adjuvant), 
and patient sociodemographic factors and other factors, such as comorbidities and insurance 
coverage that may influence the choice of treatment options for these patients.
To ensure that current CER needs could be addressed by the project, the CDC in 
collaboration with AHRQ identified a series of questions, along with the data variables 
needed to address those and other questions in comparative effectiveness research. The 
targeted CER issues were:
• Are colon and rectum (colorectal) cancer patients tested for KRAS and are the 
results used appropriately to determine treatment? What impact does KRAS testing 
have on 2-3 year survival among colorectal cancer patients?
• Are rectal cancer patients receiving radiotherapy and what is the timing of 
radiotherapy? Are disparities apparent in the appropriate neoadjuvant use of 
radiotherapy among these patients?
• Are CML patients being tested for the BCR-ABL gene and receiving appropriate 
treatment according to those results?
• Are women with breast cancer being tested appropriately for human epidermal 
growth factor receptor 2 (HER2), progesterone receptor (PR), and estrogen receptor 
(ER) status and treated accordingly?
Methods
Case Eligibility
Cases included in the CER project were male and female patients diagnosed in 2011 with 
either in situ or malignant tumors of the breast or colon/rectum or with CML (see Table 1 
for ICD-O-3 site codes and histologies2). The 10 participating states included the entire 
states of Alaska, Colorado, Idaho, Louisiana, New Hampshire, North Carolina, Rhode 
Island, and Texas, as well as 13 counties of the Sacramento region of California and 5 
metropolitan counties of Miami, Florida.
Data Variables
Population-based cancer registries routinely collect North American Association of Central 
Cancer Registries (NAACCR) standard data variables3 such as patient demographics, tumor 
characteristics, cancer stage, treatment, address of residence, and comorbidities. However, 
these data are insufficient to support contemporary comparative treatment research. Working 
together with AHRQ, the CDC identified additional data items (Table 2) that were crucial to 
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address CER questions. The final data variables included in the CER project were: expanded 
patient information such as height and weight, comorbid conditions, and smoking status; 
area-based (census tract) socioeconomic status; stage of disease (all Collaborative Stage 
version 2 [CSv2] data items that are necessary to derive the American Joint Commission on 
Cancer [AJCC] TNM and Stage for both 6th and 7th editions)4,5; tumor biomarkers of 
prognostic and predictive significance listed under CSv2 site-specific factors (SSFs)6; and 
detailed first course of cancer-directed treatment.7 For breast cancer, the SSFs included: ER 
status, PR status, number of positive ipsilateral level I–II axillary lymph nodes, presence of 
isolated tumor cells in regional lymph nodes, size of invasive component of the tumor, 
Nottingham or Bloom-Richardson tumor grade/score, HER2, response to neoadjuvant 
therapy, and multigene signature testing. For colorectal cancer, the SSFs collected were: 
carcinoembryonic antigen (CEA), clinical assessment of regional lymph nodes, presence of 
tumor deposits, tumor regression grade, circumferential resection margin (CRM), 
microsatellite instability (MSI), perineural invasion, KRAS testing, and loss of 
heterozygosity (LOH). As for CML, Janus Kinase 2 (JAK2) gene mutation was collected in 
addition to BCR-ABL testing.
In order to evaluate comparative effectiveness of treatments for cancers of the breast, colon, 
rectum, and CML, complete and accurate first course of cancer-directed treatment was 
essential. First course of cancer treatment was defined as the therapy regimen that was given 
or planned at the time of initial diagnosis, prior to disease recurrence or progression.7 While 
central cancer registries routinely collect detailed information on surgery (which often is 
performed in hospital at inpatient or outpatient settings) and radiation (hospital-affiliated and 
freestanding), other adjuvant treatments have often been missing or incomplete. Therefore, 
the CER project focused on collecting complete adjuvant treatment occurring within 12 
months of diagnosis, particularly detailed chemotherapy data. To identify each drug 
consistently across the registries, abstractors used the Cancer Chemotherapy National 
Service Center (NSC) number. The NSC is a numeric identifier for substances submitted to 
the National Cancer Institute (NCI) for testing and evaluation during its investigational 
phase and a registration number for the Developmental Therapeutics Program (DTP) 
repository. Abstractors obtained NSC numbers from the Web-based version of the 
SEER*Rx Interactive Antineoplastic Drugs Database8 that provides detailed drug 
information including generic and brand name, abbreviation, NSC number, drug category 
and subcategory and is readily available on the NCI website (http://seer.cancer.gov/
seertools/seerrx).
The CER chemotherapy variables included each chemotherapy agent's name and NSC 
number, number of chemotherapy cycles planned, total dose planned, number of doses 
received, and total dose received, start and end dates of chemotherapy, and whether 
chemotherapy was completed as planned, as well as growth factor agents (granulocyte, 
erythrocyte, and thrombocyte) that might have been given. Patient's height and weight were 
also collected, especially for CER patients receiving chemotherapy. In addition, hormonal 
therapy and biological response modifier use were documented. If any subsequent treatment 
was given within 12 months of diagnosis as a result of recurrence, all subsequent treatment 
modalities were also recorded when available.
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A CDC work group developed a data dictionary for the non-NAACCR standard variables, 
with an emphasis on capturing all cancer therapies received within 12 months of diagnosis. 
An oncologist provided consultation on the selection and definitions of additional variables 
of CER significance. Once a variable was identified as necessary and available in medical 
records, it was added to the data dictionary with a description, rationale, codes, and coding 
instructions. The work group used established, recognized guidelines for cancer data 
collection whenever possible. As an example, the SEER*Rx database was used to assign the 
NSC number for systemic therapy because it provides a consistent method to identify each 
drug. A few drugs that were either not listed in SEER*Rx or did not have an assigned NSC 
number were assigned an identifying number to be used by all registries.
Data Collection Tool and Software
The participating states use different registry software for routine data collection and have 
various database management systems. There was no existing electronic abstraction tool for 
the CER project because the non-NAACCR standard data variables had not previously been 
collected. The CER data dictionary was provided to the registries’ software vendors for 
modification of their software so that these data items could be abstracted and be 
incorporated into the registry database. Different approaches were used by the specialized 
registries based on the capability of their software vendors, experience of their information 
technology (IT) staff, reporting requirement notification process, and CDC technical 
support. As a result, each registry had its own CER-specific data abstracting tools, edit 
programs and consolidation logic. However, all registries used a standard edits metafile and 
the same record layout for data submission.
To ensure data quality and consistency CDC staff developed a set of single field and inter-
field edits that all CER participating registries ran prior to data submission.
Institutional Review Board Approvals
The collection of additional data items for the CER project was authorized by existing 
cancer reporting laws and regulations in each state. No patients were contacted for the 
project and the collection of enhanced registry data was considered by most states to be 
public health surveillance and, as such, exempt from institutional review board (IRB) 
approval requirements. One state amended its cancer registry reporting regulations to add 
the nonstandard data items to its surveillance reporting requirements. Because the CER 
project title included the word “research,” some cancer treatment facilities required further 
explanation or, in some cases, sought full IRB review.
It should be noted that while the project activities described herein did not include research, 
but focused on collection of the data needed to support CER, all subsequent data analyses, 
conducted after the completion of project, must be covered under applicable IRB 
requirements of the investigators.
Training
Training was conducted by the CDC and its contractors before data collection began. The 
objectives of the CER project were explained, and the data variables and data dictionary, 
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especially those items not routinely collected by the registries, were reviewed and discussed. 
Trainers provided instructions on data collection and coding rules, including CSv2 stage; 
SSFs, especially biomarkers such as KRAS and HER2; complete first course of treatment 
which included surgery, chemotherapy, hormonal therapy, biological response modifiers 
(including bone marrow transplant, stem cell harvest, surgical or radiation endocrine 
therapy); growth factors; and BCR-ABL tests for CML.
In addition to CDC central training, all participating specialized registries offered 
subsequent in-house training and ongoing education, depending on the needs and experience 
of their abstractors. Various training modes included workshops, webinars, webcasts, 
teleconferences, and presentations at the state cancer registrars’ associations meetings. All 
states conducted one-on-one, in-person and/or webcast training when needed, and some also 
offered onsite demonstration. The intensity and extent of training varied by registry and 
depended on their available resources. For example, one registry housed at the health 
sciences center received training, from a clinical oncology nurse, on the National 
Comprehensive Cancer Network (NCCN) treatment guidelines for each cancer by tumor 
size, nodal involvement, and distant metastasis, as well as by biomarker/prediction of 
treatment response (eg, HER2, ER/PR and KRAS) and menopausal status (breast only).9 
This training detailed first course of treatment, sequence of treatment modalities, common 
chemotherapy regimens, chemotherapy drug names, “standard” cycle and dose, and 
calculation of total dose (planned and received). In addition, the training included 
explanation and discussion on the chemotherapy “flow chart,” common side effects, and 
toxicities. Another registry created an abstracting workbook for data collection which 
provided information not contained in the data dictionary, such as treatment guidelines 
based on stage of disease and tips for interpreting laboratory reports for biomarkers. Other 
registries used highly experienced certified tumor registrars (CTRs), or combined CTR and 
registered nurse, to conduct trainings with hospital-based and non-hospital-based CER data 
collection staff. One registry had its abstractors practice CER data collection on cases 
diagnosed prior to 2011, interacted with hospital and nonhospital staff, and established 
remote access to some facilities. All participating registries conducted refresher trainings, 
after data collection was in progress, to ensure accurate and consistent interpretation of the 
information and coding of the data. Every registry designated a contact staff person to 
address CER data collection issues, answer questions, and provide clarifications.
The CDC data dictionary work group reviewed all training materials developed by the states 
to ensure accuracy and consistency. Many states shared and customized training materials 
which were made available through the CDC CER Information-Sharing Portal.
Data Collection
As noted previously, all NPCR specialized registries have legislative rules on cancer 
reporting which provide authorization to access medical records and collect cancer-related 
data variables from hospitals and nonhospital settings. Because of the vast number of cancer 
cases (more than a quarter of the annual caseload) and the large number of additional data 
variables collected, the majority of specialized registries hired and trained additional 
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abstractors for this project; many reassigned existing staff and some used a combination of 
new and existing staff.
a. Hospital—When CER data collection started in 2012, a majority of the 2011 cases were 
already reported to the central registries. Building on the routine NAACCR abstracts they 
had on the CER cases, the hospital registrars (or central registry abstractors who visited the 
hospitals where the cancer was initially diagnosed) collected as many of the additional CER 
data items as possible. Most adjuvant treatment was given after the patient was discharged 
from the hospital; it was therefore necessary for abstractors to identify the facilities and/or 
physicians who followed the patients and provided adjuvant treatments. Some registries 
requested that hospital abstractors delay their submission of CER cancer cases until after the 
first course of treatment was complete and all information that could be obtained was 
abstracted. However, most CER cases required data collection from all source documents, 
including both hospital and nonhospital settings. On very rare occasions, where hospitals 
used a unified chart system that provided inpatient and outpatient medical records in one 
single database, abstractors were able to record all therapy modalities from a single setting.
b. Nonhospital sources—Adjuvant radiation was generally obtained from hospital 
outpatient or freestanding radiation centers, while information on chemotherapy was 
obtained mostly from hospital-based or independent hematology/oncology practice groups. 
Most specialized registries hired additional data specialists to collect CER data at physician 
offices and treatment facilities. This included identifying noncancer registry reporting 
sources to be targeted for data collection, developing methods of data collection and 
coordinating with the reporting source to carry out case identification and data collection.
Registries used 3 primary methods of data collection: onsite visits for abstracting, which was 
the most common method, obtaining hard copies or securing remote access to the facility's 
electronic medical record, and, on rare occasions, transmission of data by the facility. 
Abstraction at nonhospital sources usually required an initial onsite visit to learn how to 
navigate each practice's electronic or paper medical record systems, and follow-up visits to 
capture missing information. Follow-up was also done by phone, fax, or email whenever 
possible. Multiple visits to more than one physician office were frequently necessary to 
complete the first course of chemotherapy and other adjuvant treatment. Ascertaining the 
dose for each cycle of every chemotherapy agent was very challenging, and information was 
not always available, making the calculation of total chemotherapy dose received extremely 
difficult, often necessitating multiple visits.
Once data were obtained from all sources, CER staff reviewed and edited the cases for 
accuracy, consistency, and completeness. Cases were followed back to treating physician 
and/or facility to obtain missing information. First course of treatment received within 12 
months of diagnosis was edited and consolidated so that the data could be provided for 
comparative effectiveness of treatments. Patient address of residence at the time of diagnosis 
was geocoded to census tract by each registry and used to link case data with Census Bureau 
data files for census tract level socioeconomic indicators, such as poverty level, employment 
status, and urbanization.10
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As questions or issues related to data collection occurred, each state submitted the inquiry to 
a technical assistance folder on a central CER-specific Web portal. The dedicated Web 
portal was maintained by the CER contractor and used by all participants for project-related 
information sharing and documentation. States could post questions and receive timely 
responses that could be viewed and systematically searched by all collaborators. By 
managing the technical assistance requests in this manner, all states had access to the same 
information in real time and previous issues could be reviewed as often and by as many 
CER team members as needed. The responses could also be exported to a spreadsheet 
format for use by analysts and other members. As issues arose, a CDC data items work 
group reviewed each question, drafted a consensus response, and shared with oncologists 
and contractors, as appropriate. Once the response was final, it was posted to ensure 
standardization and consistency across all states.
All registries conducted periodic review of abstracted cases throughout the study period, 
using source documents to ensure high quality data and consistent interpretation of medical 
record information. When any systemic problem was identified, the registry immediately 
issued an alert to all data collectors. If necessary, training or refresher courses were offered. 
Although most states did not perform reabstraction audits, all performed reabstraction for 
cases with missing, unknown, or questionable data.
All specialized registries also ran their data through the NAACCR Hispanic Identification 
Algorithm (NHIA)11 and the NAACCR Asian/Pacific Islander Identification Algorithm 
(NAPIIA)12 as well as participated in linkages with the Indian Health Service to improve the 
quality of their data on race and ethnicity.13
Results
Among the 10 participating states, a total of 75,042 cancer patients were diagnosed in 2011 
with breast, colon, or rectum cancer, or CML. Breast cancer accounted for 64.6% of all 
cases, about one-quarter (24.5 %) of patients were diagnosed with colon cancer, 9.5% with 
rectal cancer, and CML accounted for 1.4%. The demographic and tumor characteristics of 
these patients are shown in Table 3. The overall high percentage of female patients (80.6%) 
reflects the large number of breast cancer cases that account for almost two-thirds of the 
total CER cases. There was no difference in gender distribution for colon cancer, and a 
higher percentage of rectal cancer and CML were males. Approximately half (48.2%) of the 
colon cancer cases were diagnosed in patients 70 years and older whereas for breast cancer, 
only about a quarter (27.8%) were aged 70 or older. The majority of patients were non-
Hispanic whites (68.2%), non-Hispanic blacks, and Hispanics (of all races) each represented 
about 14%, and less than 4% were of other or unknown races. The racial/ethnic pattern was 
very similar for all 4 cancer groups.
Overall, approximately half of the patients had private insurance (including Medicare with 
private supplement or Medicare Advantage Plans), 29% had Medicare only, 10% had 
Medicaid, 2.5% had other public insurance such as Tricare, Veterans’ Affairs, or Indian 
Health Services, and less than 5% had no insurance. Breast cancer patients (54%) were most 
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likely to have private insurance whereas colon cancer patients were the least likely (38%). 
The large proportion of Medicare coverage among colon cancer patients (37%) reflects the 
older age at diagnosis compared with other cancers. Over half (54.5%) of all patients had at 
least 1 comorbidity, with the comorbid conditions being more prevalent in colorectal than 
breast cancer patients. The majority of CER patients lived in census tracts designated as 
urban or urban/rural mixed, and less than 10% lived in rural area. About 83% resided in 
census tracts with less than 20% of families having income below federal poverty 
guidelines. Information on cigarette smoking was missing in 34.5% of the patients. Among 
those with known information, 62% never smoked cigarettes, 24% were former users, and 
14% were current smokers.
There was considerable variation of tumor stage at diagnosis by cancer type. About two-
thirds (68%) of breast cancer patients were diagnosed with early stage disease (in situ and 
localized) based on the SEER Summary Stage 2000, contrasting with only 40% among 
colorectal cancer patients. Similar tumor stage pattern was observed for AJCC TNM Stage 
Group.
The distribution of cancer cases also varied greatly by state (ranging from 819 to 26,752), 
reflecting the population size of the participating states and geographic areas.
Discussion
When the National Cancer Policy Board of the IOM, National Academy of Sciences issued a 
report on Ensuring Quality of Cancer Care in 1999, it concluded that “....for many 
Americans with cancers, there is a wide gulf between what could be construed as the ideal 
and the reality of their experience with cancer care.”14 Its subsequent report of Enhancing 
Data Systems to Improve the Quality of Cancer Care15 in 2000 recommended the need for 
comprehensive cancer data systems that could be used to gauge the status of cancer care and 
measure quality. It identified 3 existing national cancer surveillance programs that could be 
used for quality improvement of cancer care. They were: the NPCR of CDC; the 
Surveillance, Epidemiology and End Results (SEER) program of the NCI; and the National 
Cancer Data Base (NCDB), sponsored by the American College of Surgeons’ Commission 
on Cancer (ACoS-CoC) and the American Cancer Society. While each of these data systems 
has its own limitations, they also each hold great potential and could be enhanced to assess 
and improve quality of cancer care in the nation.
In response to the IOM recommendations, CDC-NPCR initiated a pattern of care study, 
comparing the observed patterns of care with the accepted guidelines for localized breast 
cancer, localized prostate cancer and Stage III colon cancer, in conjunction with the 
international CONCORD Study.16-18 Subsequently the CDC, in collaboration with 
researchers from 7 central cancer registries, conducted the Breast and Prostate Cancer Data 
Quality and Patterns of Care (POC-BP) Study in 2007-2009.19 The study examined first 
course of cancer treatment received and how the patterns of care varied by patient, provider 
and other health system level factors. It also evaluated whether the care was concordant with 
nationally recognized treatment guidelines, given the presence and severity of 
comorbidities.20-24
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The NCI has also conducted patterns of care/quality of care (POC) studies since 1987 under 
a congressional mandate [Public Law 100-607, Sec. 413 (a)(2)(C) adopted November 4, 
1988]. The collection of NCI POC data is coordinated jointly by the Division of Cancer 
Control and Population Sciences and the Division of Cancer Treatment and Diagnosis. 
Using the infrastructure of SEER registries, population-based samples of cases are selected 
every year for various cancer types to evaluate the dissemination of cancer therapy or 
guideline care into community practice and to identify possible determinants of 
dissemination and variations in therapy.25 Findings from POC studies provide educational or 
training opportunities for professional societies and public health groups to improve the 
quality of cancer care and reduce disparities in treatment and survival among different 
population groups. A wide range of cancer care has been studied by NCI over the years, 
including the trends in using adjuvant multi-agent chemotherapy and tamoxifen for breast 
cancer;26 age, sex, and racial differences in the use of standard adjuvant therapy for 
colorectal cancer;27 and clinical trial participation and time to treatment among adolescents 
and young adults with cancer.28 Though it is not population-based, researchers have also 
used the NCDB to assess treatment patterns and their determinants among patients treated in 
facilities participating in the CoC-accredited cancer programs. Examples include assessing 
the importance of socioeconomic status and treatment institution in neo-adjuvant therapy for 
Stage IIIA non-small cell lung cancer29 and the impact of facility volume on therapy and 
survival for advanced cervical cancer.30
In 2009, CDC received funding to establish 10 specialized cancer registries to collect 
additional data to support CER. This CER project is the largest and most comprehensive 
data collection effort ever conducted by population-based cancer registries in the United 
States to obtain complete and detailed first course of cancer-directed treatment for breast, 
colon, and rectal cancers and CML. This project covers more than a quarter (27.3%) of the 
US population, including a very high representation among minority populations. In fact, the 
combined catchment areas of the CER project include approximately 25% of African 
Americans, 37% of Asian/Pacific Islanders, 32% of American Indians/Alaska natives, and 
44% of Hispanics living in the United States.31 This provides a unique opportunity to 
examine the patterns of care for these cancers in a racially and ethnically diverse population, 
to compare the benefits and risks of alternative treatments and care deliveries as well as to 
assess their outcomes. The project includes all newly-diagnosed cancer patients residing in 
the participating states in care settings that are representative of contemporary practice in the 
10 geographic areas across the United States. Previous projects of this nature were often 
conducted in single major medical centers or in clinical trial groups where the patients were 
not representative of all US patients, and the treatments were not representative of 
contemporary practice of both major urban cancer centers and small rural hospitals.32-34
Using population-based central cancer registries to collect data for CER has numerous 
strengths. Existing registry infrastructure and authorizing laws and regulations make it 
feasible to expedite the process, implement the procedures and collect additional cancer data 
in a timely manner. This registry infrastructure provided a baseline of well-established 
standard definitions and codes for cancer reporting, tumor staging and treatment/drugs. 
Because central cancer registries have been in place for several decades, registry staff are 
familiar with cancer reportability and the standard rules and codes. They have extensive 
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experience with medical records abstraction and are knowledgeable of various cancer 
treatment modalities, requiring fewer staff and less training. Over time, central cancer 
registries have built excellent rapport with cancer care facilities and providers, allowing 
them to gain access to the facilities and/or connect remotely to the electronic medical 
records, resulting in an efficient and cost-effective means of obtaining the additional data for 
CER. In addition, population-based registries include all newly-diagnosed cancer patients; 
therefore findings using their data or a representative sample can be generalized to the US 
general population. There are also, however, limitations. Hospitals are required to submit 
cancer cases to central registries within 6 months after diagnosis, when first course of cancer 
treatment is often still ongoing; thus only partial treatment information is recorded at the 
time of initial report. While some states ask hospitals to submit update records which 
contain the additional treatment information, most state registries do not include these 
update records due to limited staff and competing registry priorities. Information on 
adjuvant therapies, especially hormonal and chemotherapy that are provided in nonhospital 
settings, is sometimes missing or incomplete. Collecting additional data that are not standard 
registry variables but are relevant to address CER topics requires special trainings. 
Furthermore, efforts and resources spent on project-specific activities such as software 
modification, training, data edits and added data submissions compete with regular registry 
operations and functions, potentially causing delays in routine registry data collection.
Despite the limitations, the CDC and the 10 NPCR specialized cancer registries have 
demonstrated the feasibility of utilizing population-based cancer registries to support 
comparative effectiveness investigations and other research in a cost-effective and timely 
manner. Moving forward, the CDC and the specialized cancer registries will continue to 
expand the uses of registry data beyond measuring cancer burden and evaluating stage shift 
by examining diagnostic procedures and cancer treatments and assessing how different 
procedures and treatment modalities impact patient outcomes of recurrence and survival. 
Central cancer registries provide a unique population base for cancer research. In addition, 
the consolidation of data from multiple locations of care is unique to the central cancer 
registry. No other disease surveillance system in the United States is as standardized and 
comprehensive as cancer surveillance, allowing researchers to track the outcomes of 
changes in the medical care system and assess the effectiveness of public health 
interventions. The CDC's specialized cancer registries and the entire cancer registration 
program are well positioned to conduct comparative effectiveness research, evaluate patient 
outcome, and inform future medical practice.
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Table 1
Eligibility Criteria for Comparative Effectiveness Research Cases
Site ICD-O-3 Site Code Histology Behavior Sex Diagnosis Year
Breast C50.0–C50.9 All except 9050–9055, 
9140, and 9590–9992
In situ, malignant Male and female. 2011
Colon
C18.0–18.9
* All except 9050–9055, 
9140, and 9590–9992
In situ, malignant Male and female 2011
Rectum C19.9, C20.9 All except 9050–9055, 
9140, and 9590–9992
In situ, malignant Male and female 2011
Chronic Myeloid Leukemia C42.1 Include 9863, 9875, 9876, 
9945, and 9946
malignant Male and female 2011
*
Including Appendix (site code = C18.1).
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Table 2
Non-NAACCR Standard Data Variables
*





• Comorbidities: up to 10 standard NAACCR comorbidities
• Tobacco Use: cigarette, smoking tobacco products other than cigarettes (eg, pipes, cigars, kreteks), smokeless tobacco, not otherwise specified
• Socio-Economic Status Indicators
    A wide range of indicators linked to cancer incidence data from multiple US Census Bureau data files, including area level indicators for:
    • Urban/rural
    • Poverty level
    • Health insurance coverage
    • Income ranges
    • Employment status
    • Occupation and Industry data
    • Class of worker (blue collar, white collar)
Diagnostic work up for CML
• BCR-ABL Cytogenetic Result and Date
• BCR-ABL FISH Result and Date
• BCR-ABL Qualitative Result and Date
• BCR-ABL Quantitative and Date
First course treatment information:
• Chemotherapy: agent and NSC number (for up to 6 chemotherapy agents)
• Chemotherapy: number of doses planned and received (for up to 6 chemotherapy agents)
• Chemotherapy: dose amount and units planned and received (for up to 6 chemotherapy agents)
• Chemotherapy: administration start and end dates (for up to 6 chemotherapy agents)
• Chemotherapy: completion status
• Chemotherapy: Granulocyte CSF Status
• Chemotherapy: Erythrocyte Growth Factor Status and Thrombocyte Growth Factor Status
• Hormone: agent and NSC number (for up to two hormone agents)
• Biologic Response Modifier (BRM): agent and NSC number (for up to 2 hormone agents)
Subsequent/second course treatment information:
• Reason Subsequent Treatment
• Subsequent treatment date
• Subsequent Surgery
• Subsequent Radiation
• Subsequent Chemotherapy and Chemo NSC (for up to 6 chemo agents)
• Subsequent Hormone and hormone NSC (for up to 2 hormone agents)
• Subsequent BRM and BRM NSC (for up to 2 BRM agents)
• Subsequent Transplant/Endocrine
• Subsequent Other
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*
Only variables defined and collected exclusively for Comparative Effectiveness Research (CER) activities are included above. There are many 
other variables included in the CER data collection activities that are routinely collected by National Program of Cancer Registries (NPCR) and 
defined by North American Association of Central Cancer Registries' (NAACCR's) Standards for Cancer Registries, Volume II: Data Standards 
and Data Dictionary, Fifteenth Edition, Record Layout Version 12.1.
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